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Abstract 
Background: Currently, the main goal of cancer research is to increase longevity of patients suffering malignant can-
cers. The promising results of BCc1 in vitro and vivo experiments made us look into the effect of BCc1 nanomedicine 
on patients with cancer in a clinical trial.
Methods: The present investigation was a randomized, double-blind, placebo-controlled, parallel, and multicenter 
study in which 123 patients (30-to-85-year-old men and women) with metastatic and non-metastatic gastric cancer, 
in two separate groups of BCc1 nanomedicine or placebo, were selected using a permuted block randomization 
method. For metastatic and non-metastatic patients, a daily dose of 3000 and 1500 mg was prescribed, respectively. 
Overall survival (OS) as the primary endpoint and quality of life (measured using QLQ-STO22) and adverse effects as 
the secondary endpoints were studied.
Results: In metastatic patients, the median OS was significantly higher in BCc1 nanomedicine (174 days [95% confi-
dence interval (CI) 82.37–265.62]) than in placebo (62 days [95% CI 0–153.42]); hazard ratio (HR): 0.5 [95% CI 0.25–0.98; 
p = 0.046]. In non-metastatic patients, the median OS was significantly higher in BCc1 nanomedicine (529 days [95% 
CI 393.245–664.75]) than in placebo (345 days [95% CI 134.85–555.14]); HR: 0.324 [95% CI 0.97–1.07; p = 0.066]. The 
QLQ-STO22 assessment showed a mean difference improvement of 3.25 and 2.29 (p value > 0.05) in BCc1 nanomedi-
cine and a mean difference deterioration of − 4.42 and − 3 (p-value < 0.05) in placebo with metastatic and non-meta-
static patients, respectively. No adverse effects were observed.
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Background
Global statistics data in 2015 recorded 8.8 million deaths 
caused by cancer, which nearly equaled one-sixth of all 
deaths [1]. In 2018, 1,735,350 new cancer cases and 
609,640 cancer deaths are calculated to happen in the US 
[2].
Among all cancers, gastric cancer has always been a 
major clinical challenge due to poor prognosis and inef-
ficient treatments [3, 4]. Based on the National Cancer 
Database, in the United States, the overall 5-year (2008–
2014) relative survival rate of patients having stomach 
cancer was about 31% [2], new stomach cancer cases 
were 7.2 per 100,000 people per year and the death toll 
was 3.2 per 100,000 people per year in 2011–2015 [5]. It 
is estimated that 26,240 people will be added to the pre-
vious gastric cancer patients in 2018, which will be 1.5% 
of all cancer patients [5].
Approximately half of the gastric cancer occurs in East 
Asian countries, showing a higher mortality rate than 
other countries [6]. Over half of gastric cancer deaths 
happen in the first year of diagnosis in Iran and another 
30% during the second year of diagnosis. Like other 
developing countries, the results show lower survival 
rates in Iran [7].
Currently, radiotherapy, chemotherapy, surgery, or 
combinations of these are being used in cancer thera-
pies, while every one of such treatments has both pros 
and cons [8]. Despite the preference for surgical resec-
tion treatment in patients with cancer, chemotherapy is 
considered the best available treatment for recurrent and 
advanced cancer patients who are not suitable for surgery 
[4].
Although chemotherapy is widely being used in clinics, 
it has also had dissatisfactory outcomes, which are mostly 
attributed to nonspecific drug distribution to healthy tis-
sues, indiscriminate destruction of normal cells, toxicity 
of conventional chemotherapeutic drugs and the capabil-
ity of cancerous cells to pump out the drug using multi-
drug resistance mechanisms along with heterogeneity of 
cancer [9, 10].
Nanotechnology has recently revolutionized chemo-
therapy and cancer treatments [11]. Nanomedicine can 
be more effective in treatment of cancer by targeting cel-
lular characteristics of solid tumors. Using nanomedicine 
in treatments can reduce the resistant clonal population 
of cancerous cells [12, 13], so in recent years, more nano-
medicine drugs targeting cancer cells are being nomi-
nated to be approved by Food and Drug Administration 
(FDA) [10]. Having said that, nanomedicine formulations 
need to be revised in terms of efficacy [14].
Nanochelating is a mother technology [15] provid-
ing a high-yield technique with a wide range of scientific 
and technological applications [16, 17] by synthesizing 
nanostructures via self-assembly [18] and bottom-up 
method. Such nanostructures are smart molecules show-
ing favorable reactions according to the physicochemical 
conditions of the environment, which will subsequently 
modulate the balance of contained elements in cellular 
microenvironments based on their designed nanostruc-
ture [19].
In our previous study, we used this technology to syn-
thesize BCc1 [8], having chelating properties with domi-
nant affinity for iron element. Also, we evaluated the 
anticancer effects of BCc1 in vivo and vitro studies.
We observed apoptosis inducing effects on cancer cells, 
while BCc1 had no negative effects on normal cells at the 
same concentration and also showed protecting effects 
against oxidative stress.
After considering intraperitoneal (IP) lethal dose 
(LD50) of BCc1, it was revealed that BCc1 increased sur-
vival in mice bearing cancer [8].
In continuation of our preclinical studies, due to short 
longevity of patients with gastric cancer, we tested this 
nanostructure on patients suffering from gastric cancer 
[4, 20]. This investigation was conducted in the form of 
a randomized, double-blind, placebo-controlled study in 
two metastatic and non-metastatic gastric cancer groups 
to assess the overall survival (OS) and quality of life 
(QOL) in each. Along the study, any probable side effect 




The purpose of this study was comparing BCc1 nano-
medicine and placebo groups.
The study was designed based on two main groups 
(metastatic and non-metastatic gastric cancer) that 
were separately divided into two sub-groups (drug and 
placebo).
Conclusion: The findings of this trial has provided evidence for the potential capacity of BCc1 nanomedicine for 
treatment of cancer.
Trial registration IRCTID, IRCT2017101935423N1. Registered on 19 October 2017, http://www.irct.ir/ 
IRCT2017101935423N1
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A randomized, double-blind, placebo-controlled, and 
parallel trial was conducted at Cancer Research Center of 
Shahid Beheshti University of Medical Sciences.
Patients were collected from the oncology center of 
Shohadaye Tajrish Hospital, Bu Ali, Naft Company, 
Imam Reza, Firouzgar, and Shahid Fayaz Bakhsh hospi-
tals in Tehran, Iran.
All groups received BCc1 nanomedicine or placebo 
capsule in addition to the base treatment, so it didn’t 
interfere in physician’s protocol. The analysis report was 
conducted after an 18-month follow-up.
Participants
Recruitment, randomization, and allocation
Patients with adenocarcinoma gastric cancer were first 
invited to participate in the present study with a prior 
notice and then their eligibility criteria were evaluated by 
the researcher in charge.
Patients, the clinician, and the researcher in charge 
were blinded to treatment allocation. The patients were 
assigned to BCc1 nanomedicine and placebo groups 
based on the blocked randomization form [21].
Sample collection
Detailed trial information was all explained to patients by 
the researcher in charge and written informed consent 
was taken from all patients before enrollment. After that, 
all patients, already registered at Cancer Research Center 
of Shahid Beheshti University of Medical Sciences, were 
visited by the clinician, and then following the confirma-
tion of their metastatic or non-metastatic gastric cancer 
using their medical records including endoscopic ultra-
sound (EUS), computed tomography scan (CT scan), 
and positron emission tomography scan (PET scan), they 
were sent into one of the main groups.
Finally, grouping classifications for clinical (c-stage) 
and post-neoadjuvant treatment (ypStage) stages for gas-
tric adenocarcinoma were proposed for the eighth edi-
tion of the American Joint Committee on Cancer (AJCC) 
staging system guideline [22].
During the study, the patients who underwent a sur-
gery and were unable to swallow did not take any drugs 
or placebo for 3 weeks.
Inclusion criteria
• Men and women aged 25–85.
• Patients who were able to swallow.
• Patients confirmed with adenocarcinoma gastric 
cancer including gastroesophageal junction.
• Patients suffering metastatic and non-metastatic gas-
tric cancer signing the consent form.
Exclusion criteria
• Patients who declined to continue taking medicine.
• Observing adverse symptoms such as unacceptable 
toxicity in the patients after taking the medicine.
Withdrawal criteria
The patients were free to withdraw from the study at 
any time without any need to provide the reason, but 
they allowed the continuation of data collection.
Primary outcome measurement
• The primary main goal of the present study was 
OS. This period was measured from randomization 
time to death, irrespective of the cause.
Secondary outcome measurement
• Quality of life The secondary main goal included 
QOL according to the European Organization for 
Research and Treatment of Cancer (QLQ-ST22) 
questionnaire [23] once before the treatment and 
once after 1.5  months for patients with metastatic 
gastric cancer and 4 months for patients with non-
metastatic gastric cancer.
• Adverse effect Adverse effects including vomit-
ing, nausea, neutropenia, anorexia, vital signs and 
hematological and biochemical tests in blood were 
assessed and recorded in all patients.
Sample size
63 metastatic gastric cancer patients, out of whom 33 
received BCc1 nanomedicine and 30 received placebo, 
were recruited randomly for the present study. In addi-
tion, 60 non-metastatic gastric cancer patients, out of 
whom 30 received BCc1 nanomedicine and 30 received 
placebo, were recruited randomly.
Follow‑up visits
All patients were followed up on phone calls on a 
weekly basis and were also visited by the clinician 
repeatedly. In addition, patients were free to consult 
with the researcher in charge for any reason at any 
time, including the occurrence of an adverse event.
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Data collection
The researcher in charge collected the information 
and checked for the missing values and consistency in 
patients during the study. Full details of data manage-
ment procedures are available at any time.
Intervention
Both BCc1 and placebo capsules were exactly identical in 
terms of shape and size. The treatment doses were speci-
fied according to “Guidance for Industry Estimating the 
Maximum Safe Starting Dose in Initial Clinical Trials for 
Therapeutics in Adult Healthy Volunteers” guideline [24].
In the previous animal study, we obtained LD50 for 
BCc1 nanomedicne (Additional file  1) by which we 
acquired No Observed Adverse Effect Level (NOAEL) for 
clinical study. The most famous and applicable method 
to adjust effective animal dose to human dose is calculat-
ing the effective animal dose for body surface area based 
on mg/m2. Therefore, we considered LD50 the refer-
ence to normalize the effective dose and then calculated 
it based on mg/m2, we chose the lowest dose at the safe 
range as first-in-human (FIH) for non-metastatic patients 
and highest dose at the safe range as FIH for metastatic 
patients [24].
A daily dose of 3000  mg was used for metastatic 
patients and 1500  mg for non-metastatic patients at 
three servings. The patients were monthly provided with 
medicine free of charge, while the researcher in charge 
Fig. 1 Consort flow diagram for patients with metastatic gastric cancer
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became sure the patients took the medicine in the previ-
ous months.
Active pharmaceutical ingredient (API) synthesis of 
BCc1 nanomedicine was done in Sodour Ahrar Shargh 
Company’s laboratory using nanochelating technology 
[15] and then it was capsulized in Tehran Darou Phar-
maceutical Co. in Tehran, Iran. Yet, both synthesizing 
and capsulizing placebo API were done in Tehran Darou 
Pharmaceutical Co. in Tehran, Iran.
Statistical methods
The Kaplan–Meier [25] and Lifetime Table were used for 
construction of survival curves, and comparisons were 
performed using the log-rank test [26]. Hazard ratios 
(HRs) and 95% confidence interval (CI) were derived 
from cox proportional hazards models stratified by the 
two randomization stratification factors [27].
For QOL, first, the mean scores for all patients were 
calculated and then compared between the two groups 
(BCc1 nanomedicine and placebo) with Paired Samples 
T-Test (parametric statistic) and Wilcoxon Signed Ranks 
Test (non-parametric statistic) used for statistical com-
parison. A p-value of ≤ 0.05 was considered significant 
for covariate selection. All analyses were conducted using 
SPSS software (version 25; SPSS Inc., Chicago, IL, USA) 
[28].
Fig. 2 Consort flow diagram for patients with non-metastatic gastric cancer
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Results
Patients’ disposition and characteristics
The patients were recruited between October 26, 2016 
and May 19, 2018. The average ages for metastatic BCc1 
nanomedicine and placebo groups at stage IV were 
59.8 ± 13 and 61.2 ± 12.93, respectively, and in non-met-
astatic BCc1 and placebo groups at stages I, II, and III the 
average ages were 65 ± 10.5 and 61 ± 11.4, respectively.
As shown in Figs.  1 and 2, the number of all patients 
who were initially recruited on a random basis was 148, 
out of whom 25 were excluded from the study because of 
ineligibility, incomplete histological confirmation, among 
other reasons (These tables are prepared according to 
Consolidated Standards of Reporting Trials Form) [29]. 
The metastatic and non-metastatic patients’ characteris-
tics are shown in Tables 1 and 2.
Overall survival
As shown in Table 3A, in metastatic patients, the median 
OS in BCc1 nanomedicine and placebo patients was 
174 [95% CI 82.37–265] and 62 days [95% CI 0–153.42], 
respectively, thus the results showed that in meta-
static patients who took BCc1 capsules, the median OS 
was 112  days significantly higher than that of patients 
who took placebo capsules; HR: 0.5 [95% CI 0.25–0.98; 
p = 0.046]. Kaplan–Meier diagram of survival and haz-
ard function diagram of metastatic patients are shown in 
Fig. 3a, b.
Likewise, as shown in Table  3A, in non-metastatic 
patients the median OS in BCc1 and placebo patients 
was 529 [95% CI 393–664] and 345 days [95% CI 134.85–
555.147], respectively, thus the results showed that in 
non-metastatic patients who took BCc1 capsules, the 
median OS was 184 days significantly higher than that of 
patients who took placebo capsules; HR: 0.324 [95% CI 
0.97–1.07; p = 0.066]. Kaplan–Meier diagram of survival 
and hazard function diagram of non-metastatic patients 
are shown in Fig. 4a, b.
As shown in Table  3B, in metastatic patients, 48.5% 
of patients in BCc1 nanomedicine group and 63.3% in 
placebo group, and in non-metastatic patients, 12.9% in 
BCc1 nanomedicine group and 29.6% in placebo group 
died during the study.
In the same study, we did an analysis to investigate 
patients’ OS who received BCc1 nanomedicine or pla-
cebo and chemotherapy (three types of regimens FOL-
FOX, DCF, and FLOT) simultaneously.
As shown in Table  4A, in metastatic patients, the 
median OS in BCc1 and placebo patients was 302 [95% 
CI 40.87–563.13] and 107  days [95% CI 0–214.98], 
respectively, while they underwent chemotherapy at 
the same time. The results revealed that in metastatic 
patients who took BCc1 capsules and simultaneously 
underwent chemotherapy, the median OS was 195  days 
longer, although not significantly, than the median OS 
of those who received placebo capsules and chemo-
therapy at the same time; HR: 0.589 [95% CI 0.212–1.64; 
p = 0.311]. Kaplan–Meier diagram of survival and hazard 
function diagram of metastatic patients who received 
BCc1 nanomedicine or placebo and underwent chemo-
therapy at the same time are shown in Fig. 5a, b.
However, as shown in Table  4A, in non-metastatic 
patients, the median OS in BCc1 and placebo patients 
was 482 and 265  days [95% CI 210.57–319.42], respec-
tively, thus in non-metastatic patients who took BCc1 
capsules and simultaneously underwent chemotherapy, 
the median OS was 217 days significantly longer than the 
median OS of those who received placebo and chemo-
therapy at the same time; HR: 0.019 [95% CI 0–0.065; 
p = 0.207]. Kaplan–Meier diagram of survival and haz-
ard function diagram of non-metastatic patients who 
received the interventions (BCc1 nanomedicine or pla-
cebo) and underwent chemotherapy at the same time are 
shown in Fig. 6a, b.
As shown in Table 4B, in metastatic patients, 50% of 
patients in BCc1 nanomedicine and 53% in placebo, 
and in non-metastatic patients, no patients in BCc1 







 Mean (SD) 59.8 ± 13 61.2 ± 12.93
Weight
 Mean (SD) 61.68 ± 12.24 55.62 ± 12.82
Gender (n)
 Male–female 23–10 20–10
Metastatic site (n)
 Liver 17 11
 Multiple site 9 10
 Lung 2 3
 Peritoneal carcinomatosis 5 4
Stage 4 (n) 33 30
 Site of involvement (n)
  Cardia 7 10
  Antrum 6 5
  Fundus 3 3
  Greater curvature 3 4
  Lesser curvature 4 3
  Diffuse 4 5
Intervention + chemotherapy (n) 14 19
Intervention + chemotherapy + 
radiotherapy (n)
0 1
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nanomedicine and 35% in placebo died during the 
study, while patients of these groups received the inter-
ventions (BCc1 nanomedicine or placebo) and under-
went chemotherapy at the same time.
In the same study, we did an analysis to investi-
gate patients’ OS who received only interventions 
(BCc1 nanomedicine or placebo) without undergoing 
chemotherapy.
As shown in Table  5A, the results revealed that in 
metastatic patients who only took BCc1 capsules, the 
median OS was 122  days significantly longer than the 
median OS of those who received only placebo cap-
sules. Kaplan–Meier diagram of survival and hazard 
function diagram of metastatic patients who received 
only intervention (BCc1 nanomedicine or placebo) are 
shown in Fig. 7a, b.
On the other hand, as shown in Table  5A, in non-
metastatic patients who only took placebo capsules, the 
median OS was 12  days longer, although not signifi-
cantly, than the median OS of those who received BCc1. 
Kaplan–Meier diagram of survival and hazard function 
diagram of non-metastatic patients who received only 
intervention (BCc1 nanomedicine or placebo) are shown 
in Fig. 8a, b.
As shown in Table  5B, in metastatic patients, 49% of 
patients in BCc1 nanomedicine and 63% in placebo, and 
in non-metastatic patients, 13% in BCc1 nanomedicine 
and 30% in placebo died during the study, while patients 
of these groups received only the medicine (BCc1 nano-
medicine or placebo), without undergoing chemotherapy.
The results of Cox multivariate regression model 
are shown in Table  6. In part A of Table  6, HR of 
BCc1 nanomedicine equals 0.476 [95% CI 0.24–0.96; 
p = 0.039]. This value of HR indicates that in metastatic 
patients, the hazard of mortality for those who took 
BCc1 nanomedicine is 0.476 times more than that of 
those who took placebo. Likewise, in part A of Table 6, 
HR of chemotherapy equals 0.737 [95% CI 0.37–1.47; 
p = 0.388]. This value of HR indicates that in metastatic 
patients, the hazard of mortality for those who under-
went chemotherapy is 0.737 times more than that of 
those who did not receive chemotherapy.







 Mean (SD) 65 ± 10.5 61 ± 11.4
Weight
 Mean (SD) 62 ± 14 59 ± 11
Gender (n)
 Male–female 20–10 14–19
Stage (n)
 I 3 1
 II 3 8
 III 19 13
Site of involvement (n)
 Cardia 10 9
 Antrum 9 6
 Fundus 0 3
 Greater curvature 3 1
 Lesser curvature 7 5
 Diffuse 2 2
Intervention + chemotherapy (n) 12 20
Intervention chemotherapy + 
radiotherapy (n)
1 2
Table 3 (A) Median of overall survival analysis in all metastatic and non-metastatic gastric cancer patients in the whole 
study. (B) Death percentage analysis in all metastatic and non-metastatic gastric cancer patients in the whole study
Test of equality of survival distributions (for Bcc1 and placebo groups) assay with Log Rank (Mantel-Cox)
Group Metastatic Non‑metastatic
Total number BCc1 (n = 33) Placebo (n = 30) BCc1 (n = 30) Placebo (n = 30)
(A) Median of overall survival analysis
Median (days) 174 62 529 345
Std. error 46.748 46.643 69.263 107.218
Median 95% CI (lower) 82.374 0.000 393.245 134.854
Median 95% CI (upper) 265.626 153.421 664.755 555.146






(B) Death percentage analysis
Death percentage 48.5% 63.3% 12.9% 29.6%
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As shown in part B of Table  6, HR of BCc1 equals 
0.268 [95% CI 0.07–1.04; p = 0.057]. This value of HR 
indicates that in non-metastatic patients, the hazard 
of mortality for those who took BCc1 nanomedicine is 
0.268 times more than that of those who took placebo. 
Likewise, in part B of Table  6, HR of chemotherapy 
Fig. 3 a Kaplan–Meier diagram of survival. b Hazard function diagram in metastatic patients (Lifetime tables of hazard and survival for patients who 
received BCc1 nanomedicine show a higher survival and lower hazard than patients who received placebo)
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equals 1.494 [95% CI 0.42–5.32; p = 0.535]. This value 
of HR indicates that in non-metastatic patients, the 
hazard of mortality for those who underwent chemo-
therapy is 1.494 times more than that of those who did 
not receive chemotherapy.
Adverse effects
The adverse effects including vomiting, nausea, neutro-
penia, and anorexia were not observed in patients in each 
treatment arm.
During the follow-up, no diarrhea was observed and 15 
non-metastatic patients in BCc1 claimed an increase in 
Fig. 4 a Kaplan–Meier diagram of survival. b Hazard function diagram in non-metastatic patients (Lifetime tables of hazard and survival for patients 
who received BCc1 nanomedicine show a higher survival and lower hazard than patients who received placebo)
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appetite and also there were no adverse events leading to 
death in placebo and BCc1 nanomedicine. The results of 
the whole blood, renal function, biochemical results, and 
hepatic function are shown at Table 7A–D respectively.
Quality of life
The global life quality of all patients was analyzed based 
on EORTC QLQ-C22 form including dysphagia scale, 
eating restrictions scale, anxiety scale, dry mouth, taste, 
and hair loss topics and in this form, lower scores indi-
cated better global QOL.
Before randomization, all patients filled out EORTC 
QLQ-C22 form once, saved as “before form” in patients’ 
documents. In patients who received the treatment, the 
form was filled out once more after 1.5 and 4  months 
for metastatic and non-metastatic patients, respectively, 
saved as “after form” in patients’ documents.
As shown in Table  8, the mean difference (before-
after) of global QOL improved (3.25, p > 0.05) in meta-
static patients who received BCc1, but it became worse 
(− 4.421, p < 0.05) in patients who received placebo. 
Likewise, as shown in Table  9, the mean difference 
(before-after) of global QOL improved (2.29, p > 0.05) 
in non-metastatic patients who received BCc1, but it 
became worse (− 3, p < 0.05) in patients who received 
placebo.
In the same study, we did an analysis to investigate 
patients’ QOL who received intervention (BCc1 or pla-
cebo) and chemotherapy simultaneously.
As shown in Table  10, the mean difference (before-
after) of global QOL improved (1.66, p > 0.05) in meta-
static patients who received BCc1 and chemotherapy 
simultaneously, but it became worse (− 0.75, p > 0.05) in 
patients who received placebo and chemotherapy at the 
same time. Likewise, as shown in Table 11, the mean dif-
ference (before-after) of global QOL improved (0.714, 
p > 0.05) in non-metastatic patients who received BCc1 
and chemotherapy simultaneously, but it became worse 
(− 3.83, p < 0.05) in patients who received placebo and 
chemotherapy at the same time.
Discussion
Scientists all around the world have discovered a human 
genome map by mixing forces, which has had a dramatic 
effect on production of current medicine. It has also 
broadened the views leading to advancement of making 
new drugs and biological agents [30]. These new drugs, 
despite humane genomes’ variability, must be capable to 
overcome various and special mechanisms causing dis-
eases in every individual person.
Nanotechnology provides new approaches aiming 
for reduction of adverse effects of systemic delivery and 
Table 4 (A) Analysis of  median of  overall survival received interventions (BCc1nanomedicine or  placebo) 
and  chemotherapy simultaneously. (B) Death rate analysis received interventions (BCc1nanomedicine or  placebo) 
and chemotherapy simultaneously
Test of equality of survival distributions (for Bcc1 and placebo groups) assay with Log Rank (Mantel-Cox)
a No statistics are computed because all cases are censored
b Univariate cox regression model
Group Metastatic Non‑ metastatic
Total number BCc1(n = 14) Placebo (n = 19) BCc1(n = 12) Placebo (n = 20)
(A) Median of overall survival analysis
Median (days) 302 107 482 265
Std. error 133.23 55.09 –a 27.769
Median 95% CI (lower) 40.87 0 –a 210.573
Median 95% CI (upper) 563.13 214.98 –a 319.427







 I 0 0 0 0
 II 0 0 0 3
 III 0 0 11 10
 IIII 14 19 0 0
(B) Death rate analysis
Death rate (%) 50 53 0 35
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improvement of efficacy [14, 31]. Nowadays, due to the 
heavy side effects of normal tissues in cancer therapy, 
produced by a conventional therapeutic dose of anti-
tumor drugs, scientists are inclined to use targeted nano-
drug-delivery systems [30].
The results of an animal study, conducted by Chen LC, 
revealed that intravenous administration of (188) Re-
liposome could be beneficial and is considered a useful 
approach to delivering passive nano-targeted radio thera-
peutics in oncology applications [32].
Fig. 5 a Kaplan–Meier diagram of survival. b Hazard function diagram in metastatic patients who received intervention (BCc1nanomedicine or 
placebo capsule) and chemotherapy simultaneously
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Doxil®  (liposomal doxorubicin) in 1995 and 
 Onivyde®  (liposomal irinotecan) in 2015 were the first 
generation of nanomedicine receiving clinical approval in 
the last two decades [33, 34].
The results of a meta-analysis disclosed that liposo-
mal doxorubicin-based chemotherapy is associated with 
a significant reduction in the risk of cardio toxicity [35]. 
The FDA recently approved that nano liposomal iri-
notecan combined with fluorouracil/folinic acid can sig-
nificantly prolong progression of free survival and OS in 
comparison to fluorouracil/folinic acid [36].
Fig. 6 a Kaplan–Meier diagram of survival. b Hazard function diagram in non-metastatic patients who received intervention (BCc1nanomedicine or 
placebo capsule) and chemotherapy simultaneously
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The nanochelating technology, patented [15] as a new 
approach, is proving to have a significant role in treat-
ment of different diseases by synthesizing different nano-
structures that possess effective properties. The very 
same nanostructures have some physical and chemical 
properties such as saturation solubility, dissolution rate, 
crystal form, particle surface hydrophobicity, and hydro-
phobicity physical response [37].
Nano particles that are produced by nanochelating 
technology are biodegradable and/or biocompatible and 
are synthesized using controlled self-assembly method 
[38]; as a result, the nanostructures produced by this 
method are completely unique because it is so powerful 
in chemistry protocols and can synthesize organic and 
inorganic building blocks into unprecedented structures 
and patterns [10].
In the previous study, BCc1 nanomedicine was 
designed based on the nanochelating technology for 
cancer treatment experimented in vitro and vivo stud-
ies and the results showed that BCc1 has high poten-
tials to induce therapeutic behavior [8].
According to some data in 2013–2015, almost 0.8% of 
people will be diagnosed with stomach cancer at some 
point in their lifetime, so we investigated the effects of 
this nanomedicine in patients with gastric cancer [2].
BCc1 is the only nanomedicine that is designed and 
used in the domain of human cancers based on self-
assembly method [38, 39]. Even in the most interiors of 
cancer stem cells (CSC) niches, nanomedicines are capa-
ble of delivering drug molecules and transcending the 
limitations of conventional free drug delivery approaches 
[40].
Most drug-resistant cancer cells and CSCs show high 
levels of CD44 receptor which binds hyaluronate [41]. 
CD44 is potentially able to be targeted for the treatment 
of drug-resistant tumors and CSC [42]. The results of 
the previous study revealed that BCc1 can reduce CD44 
expression in cancer cell line; as a result, we can assume 
that BCc1 is able to affect CSCs [8].
One of the properties of BCc1 is chelating iron which 
can arrest G1/S phase and cause the death of cancer 
cells using apoptosis mechanism, while no apoptosis was 
observed in normal cells with an identical BCc1 dose [8]. 
In the present study, BCc1 nanomedicine does not have 
any side effects like nausea, diarrhea, vomiting, and ano-
mie in patients with gastric cancer.
OS could be considered the primary endpoint of can-
cer treatment in the present and future [29]. BCc1 has 
already proved that it is able to increase the survival 
rates and decrease metastasis in mice bearing adenoma 
carcinoma. In the present study, in order to investigate 
the effect of BCc1 nanomedicine on OS at a clinical trial 
(randomized and placebo controlled), some patients with 
metastatic and none-metastatic gastric cancer were ana-
lyzed after taking BCc1 nanomedicine. It was shown that 
BCc1 nanomedicine can increase median OS compared 
Table 5 Median of overall survival analysis of patients who only received intervention: (A) BCc1 nanomedicine or Placebo 
without  chemotherapy. (B) Death percentage analysis of  patients who only  received intervention: BCc1 nanomedicine 
or Placebo without chemotherapy
Test of equality of survival distributions for (Bcc1 an0d placebo groups) assay with Log Rank (Mantel-Cox)
Group Metastatic Non‑metastatic
Total number BCc1(n = 19) Placebo (n = 11) BCc1(n = 18) Placebo (n = 10)
(A) Median of overall survival analysis
Median (days) 174 52 442 454
Std. error 46.75 46.64 41.43 44.635
Median 95% CI (lower) 118.40 0 361 366
Median 95% CI (upper) 229.59 113.69 523 541







 I 0 0 3 1
 II 0 0 3 4
 III 0 0 8 3
 IIII 19 11 0 0
(B) Death rate analysis median of overall survival analysis
Death rate (%) 49 63 13 30
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to placebo, both in metastatic and none-metastatic gas-
tric cancer patients.
As shown in Kaplan–Meier diagram for metastatic 
patients, half of the deaths in patients who took pla-
cebo capsules occurred in the first 30  days of the 
study, but half of the deaths in patients who took BCc1 
nanomedicine occurred in the first 50 days (Fig. 3). In 
addition, as shown in Kaplan–Meier diagram for non-
metastatic patients, half of the deaths in patients who 
took placebo capsules occurred in the first 3 months of 
the study, but half of the deaths in patients who took 
Fig. 7 a Kaplan–Meier diagram of survival. b Hazard function diagram in metastatic patients who only received interventions (BCc1 nanomedicine 
or placebo) without undergoing chemotherapy
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BCc1 nanomedicine occurred in the first 6  months 
(Fig. 4).
In conclusion, in both metastatic and non-metastatic 
patients, those who took BCc1 nanomedicine lived 
longer than those who took placebo.
As confirmed by ethics committee, no treatment 
was removed from the study and a number of patients 
received chemotherapy simultaneously both in BCc1 
nanomedicine and placebo groups. To investigate the 
simultaneous effect of chemotherapy and intervention 
(BCc1 or placebo) on OS, an analysis was conducted on 
Fig. 8 a Kaplan–Meier diagram of survival. b Hazard function diagram in non-metastatic patients who only received interventions 
(BCc1nanomedicine or placebo) without undergoing chemotherapy
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the data revealing that in patients with metastatic gas-
tric cancer, the median OS was significantly longer, in 
patients who simultaneously received chemotherapy 
and BCc1 than those who received chemotherapy and 
placebo at the same time. The analysis also showed 
that in patients with none-metastatic gastric cancer, 
the median OS was longer, although not significantly, 
in patients who simultaneously received chemotherapy 
and BCc1 nanomedicine than those who simultane-
ously received chemotherapy and placebo.
These results prove the hypothesis that there is syner-
gism effect between mechanisms of BCc1 nanomedicine 
and conventional treatments like chemotherapy.
To investigate the effect of BCc1 nanomedicine on OS, 
an analysis was conducted on the data revealing that in 
patients with metastatic and non-metastatic gastric can-
cer, those who only received BCc1 without chemotherapy 
lived longer, which shows the therapeutic effect of BCc1 
nanomedicine. This finding can be the subject of future 
clinical trials with a larger number of patients.
QOL measures provide helpful information of global 
well-being and functional status of patients, which is 
why QOL is critical for complete evaluation of new 
treatments for patients with cancer [29, 43].
The study findings revealed that the BCc1 group 
enjoyed more improvement, regarding global QOL, in 
comparison with the placebo group in both metastatic 
and none-metastatic groups.
As the results show, the similar QOL and OS improve-
ment pattern proves the positive effect of BCc1 nano-
medicine on these patients.
A potential limitation of the trial was the point that 
because the patients suffered gastric cancer at metastatic 
stage, taking 3 capsules in each serving was hard for 
them; therefore, in the future, it is recommended to use 
BCc1 nanomedicine for gastric cancer patients (end stage 
and metastatic) through other application methods.
Table 6 Cox multivariate regression model. (A) metastatic gastric cancer patients. (B) Non-metastatic gastric cancer 
patients
Variables in the equation
B df Sig. Exp(B) 95.0% CI
Lower Upper
(A) Cox multivariate regression model for metastatic gastric cancer
BCc1 nanomedicine indicator − 0.743 1 0.039 0.476 0.235 0.962
Chemotherapy indicator − 0.306 1 0.388 0.737 0.368 1.474
(B) Cox multivariate regression model for non-metastatic gastric cancer
BCc1 nanomedicine indicator − 1.316 1 0.057 0.268 0.069 1.042
Chemotherapy-indicator 0.401 1 0.535 1.494 0.420 5.315
Table 7 Whole blood (A), renal function (B), biochemical 
results (C) and  hepatic function (D) of  the  patients 
who took BCc1 nanomedicine revealed that  none 
of the patients suffered deficiency
Index Unit Amount
(A) Whole blood function
WBC ×1000/mm3 5.1 ± 1.3
RBC Mill/mm3 4.4 ± 0.6
HGB g/dl 12.5 ± 1.8
HCT % 40.1 ± 4.5
MCV Fl 88.4 ± 10.2
MCH pg 28.8 ± 4.3
MCHC g/dl 32.9 ± 1.8
Platelet ×1000/mm3 195 ± 27
RDW 43 ± 21.1
PDW Fl 13.3 ± 0.8
MPV Fl 10 ± 1.6
(B) Renal function
Urea mg/dl 30.4 ± 13.6
Creatinine mg/dl 1.0 ± 0.1
(C) Biochemical function
Iron µg/dl 56 ± 15
TIBC µg/dl 314 ± 30
UIBC µg/dl 258 ± 10
Ferritin ng/dl 250 ± 80
Sodium mmol/l 139 ± 7
Potassium mmol/l 4.1 ± 0.7
Chloride mmol/l 105 ± 10
(D) Hepatic function
Triglycerides mg/dl 102 ± 48
Total cholesterol mg/dl 183 ± 22
AST (SGOT) U/l 19.1 ± 5.1
ALT (SGPT) U/l 14.3 ± 4.3
Alkaline phosphatase IU/l 286.6 ± 95
Bilirubin (total) mg/dl 0.725 ± 0.09
Bilirubin (direct) mg/dl 0.2 ± 0.1
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Table 8 (A) Quality of life of metastatic gastric cancer patients, (B) Median difference before–after of quality of Life














(A) Quality of life in patients with metastatic gastric cancer
Global quality
(BCc1 nanomedicine)
48.88 13.614 2.779 0.118 45.63 11.009 2.247 0.200
Global quality
(Placebo)
47.16 13.280 3.047 0.200 51.58 12.384 2.841 0.200
Mean* Std. deviation Std. error mean P‑value
(B) Median difference (before–after) of quality of life
Quality of BCc1 (before–after) 3.250 8.975 1.832 0.089
Quality of Placebo (before–
after)
− 4.421 6.947 1.594 0.013
Table 9 (A) Quality of life of non-metastatic gastric cancer patients, (B) Median difference before–after of quality of Life














(A) Quality of life in patients with non-metastatic gastric cancer
Global quality
(BCc1 nanomedicine)
40.75 9.013 1.840 0.118 38.46 9.532 9.013 0.200
Global quality
(Placebo)
47.11 12.009 2.831 0.200 50.11 14.046 12.009 0.200
Mean* Std. deviation Std. error mean P‑value
(B) Median difference (before–after) of quality of life
Quality of BCc1
(before–after)
2.29 5.497 1.122 0.053
Quality of Placebo
(before–after)
− 3 12.009 2.831 0.038
Table 10 (A) Quality of  life of  metastatic gastric cancer, (patient’s received intervention and  chemotherapy 
simultaneously). (B) Median difference before –after of Quality of Life














(A) Quality of life in patients with metastatic gastric cancer
Global quality
(BCc1 nanomedicine)
45.89 12.869 4.290 0.200 44.22 10.721 3.574 0.200
Global quality
(Placebo)
49.08 13.318 3.844 0.200 49.83 13.265 3.829 0.200
Mean* Std. deviation Std. error mean P‑value
(B) Median difference (before–after) of quality of life
Quality of BCc1 (before–after) 1.667 7.053 2.351 0.499
Quality of Placebo (before–
after)
− 0.750 2.958 0.854 0.399
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Conclusion
The findings of the present study reveals that BCc1 nano-
medicine could have a positive effect on QOL and OS 
without any side effects in patients with cancer in addi-
tion to its therapeutic effects as a medicine alone and also 
BCc1 nanomedicine could have synergism effects when 
used with chemotherapy drugs at the same time. Com-
plementary studies in the future would hopefully confirm 
the effectiveness of our new nanomedicine for cancer 
treatment.
Additional file
Additional file 1. BCc1 nanomedicine toxicity report (Oral 
LD50 = 1776.59 mg/kg).
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